Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4 [18]

American Journal of Gastroenterology

Volumn 95, Issue 11, 2000, Pages 3326-3327

  Arnott, Ian D R ^a   Shand, Alan ^a   Ghosh, Subrata ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; INFLIXIMAB; PREDNISOLONE;

ADOLESCENT; ADULT; ANTIGEN PRESENTING CELL; CLINICAL ARTICLE; CROHN DISEASE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

EID: 0033761339     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)02118-3     Document Type: Letter

References (6)

1. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
2. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group
3. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions
4. Combination therapy of pentoxifylline and TNFalpha monoclonal antibody in dextran sulphate-induced mouse colitis
5. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease
6. Mutant p53 protein, Bcl-2/Bax ratios and apoptosis in paediatric acute lymphoblastic leukaemia